RxDoctor Payments DataLook up a doctor →

Melita Tate

Internal Medicine · Tulsa, OKNPI 1740289966

Payments from drug & device makers

$9,148,027in general payments, 2019–2025

Across 4,385 payments — averaging $2086.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$7.9M
  • Eli Lilly$609K
  • AstraZeneca$393K
  • Evofem Biosciences, Inc.$110K
  • H. Lundbeck A S$82K
  • Swing Therapeutics, Inc.$12K
  • plus $3K from 8 others
$2,203in research payments, 2019–2025

Across 1 payment — averaging $2203.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,148,027 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Other internal medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →